UBS Group
SGTX

UBS Group’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

UBS Group’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-54
Closed -$658 – 10316
2023
Q1 		$658 Buy
+54
New +$561 ﹤0.01% 8935
2022
Q2 		– Sell
-198
Closed -$4K – 11392
2022
Q1 		$4K Sell
198
-304
-61% -$6.77K ﹤0.01% 9377
2021
Q4 		$18K Buy
502
+425
+552% +$24.2K ﹤0.01% 8024
2021
Q3 		$6K Sell
77
-144
-65% -$11.1K ﹤0.01% 8479
2021
Q2 		$31K Buy
221
+103
+87% +$18.1K ﹤0.01% 6909
2021
Q1 		$34K Buy
118
+78
+195% +$31K ﹤0.01% 6913
2020
Q4 		$25K Buy
+40
New +$18.1K ﹤0.01% 6790

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's SGTX Position: Q2 2023 in Review

UBS Group sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 54 shares — an estimated $658 sold.

UBS Group first reported a position in SGTX in Q4 2020 and held it in 7 quarters. The position peaked at $34K in Q1 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

  • UBS Group reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 54 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $658.
  • UBS Group first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • UBS Group's Sigilon Therapeutics, Inc. Common Stock position peaked at $34K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.